Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Compass Pathways

Psilocybin Therapy Could Be FDA-Approved by Early 2027 — Here Is the Realistic Timeline for Patients Waiting Now

COMP360 psilocybin therapy could win FDA approval by early 2027. Here's the realistic submission and review timeline for patients with treatment-resistant depression waiting now.

Medical Daily

Psilocybin Could Become the First FDA-Approved Psychedelic Therapy Within Months — Here Is What Patients Need to Know

Psilocybin could receive FDA approval by late 2026 following a Trump executive order and priority review vouchers. Here's what the evidence shows and what it means for patients.

Medical Daily

The FDA Just Put Psilocybin and an MDMA-Like Drug on a 1-to-2 Month Approval Track. A Historic Mental Health Decision Is Coming.

FDA issued National Priority Vouchers to Compass Pathways, Usona, and Transcend for psilocybin and methylone in April 2026. A decision could come by late 2026.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Chicago's VA Hospital Just Enrolled Its First Veterans in a Psilocybin-Assisted Therapy Program — And the Science Behind Their PTSD Treatment Is Changing Psychiatry

A new VA clinical trial in Chicago is testing psilocybin-assisted therapy for treatment-resistant PTSD, offering hope to veterans.

Medical Daily

The FDA Is Now Fast-Tracking Magic Mushroom Drugs for Depression, Joe Rogan Claims Credit for the Idea

Donald Trump signed an order speeding FDA research on psychedelic mental health treatments after a Joe Rogan text, drawing industry praise and scientific caution.

International Business Times UK

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

MarketBeat

Compass Pathways Q1 Earnings Call Highlights

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved. On the company’s first-quar

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?

Barchart

This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

MarketBeat

Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

Barchart

Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.

Barchart

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

MarketBeat

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Barchart

Compass Pathways Stock Is Plunging Today: What's Going On?

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.

Barchart

1 Biotech Stock Under $10 That Could Surge 420%

Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.

Evening Standard

World's largest trial into whether magic mushrooms can treat depression launched at London hospital

Scientists hail 'milestone' in mental health research as new site opens at Maudsley hospital in Camberwell

The Guardian - UK

Is the therapeutic potential of hallucinogens risky and overhyped?

As the medicinal use of psychedelics gains mainstream attention, fears remain over their effect on mental health and the need for safe administration

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Magic mushroom ingredient could help treat anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests

The Independent UK

Psilocybin may be a potential treatment for anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests.

Evening Standard

Magic mushrooms compound ‘effective at treating depression in cancer patients’

Largest ever trial of psilocybin offers hope of treatment to cancer patients with major depressive disorder

Financial Times

Anorexia is the deadliest psychiatric disorder. Could psychedelics help?

A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment

Fortune

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Inverse

A single dose of psilocybin may alleviate major depression for 12 weeks, study finds

A psilocybin-based drug for treatment-resistant depression may be one step closer to approval, researchers say.

Benzinga

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.